Empagliflozin in CFRD: Efficacy and Safety of SGLT2 Inhibitor Therapy in Overweight and Obese Subjects With Cystic Fibrosis-related Diabetes: a Pilot Study.

This article discusses a clinical trial, NCT06149793, that is investigating the use of empagliflozin therapy in overweight/obese patients with cystic fibrosis-related diabetes (CFRD). The trial is a placebo-controlled, randomized, double-blind study with a 4-week washout period. The primary focus of the trial is to assess the safety and tolerability of the treatment. The trial is expected to provide valuable information for future research. The trial is being conducted in the United States and is not currently recruiting participants. [Extracted from the article]

Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)